Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Non-conventional Tropical Fruits: Characterization, Antioxidant Potential and Carotenoid Bioaccessibility.

Berni P, Campoli SS, Negri TC, de Toledo NMV, Canniatti-Brazaca SG.

Plant Foods Hum Nutr. 2019 Mar;74(1):141-148. doi: 10.1007/s11130-018-0710-1.

PMID:
30644024
2.

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C.

J Immunol Res. 2018 Oct 29;2018:5804230. doi: 10.1155/2018/5804230. eCollection 2018.

3.

Pattern recognition analysis on long noncoding RNAs: a tool for prediction in plants.

Negri TDC, Alves WAL, Bugatti PH, Saito PTM, Domingues DS, Paschoal AR.

Brief Bioinform. 2019 Mar 25;20(2):682-689. doi: 10.1093/bib/bby034. Review.

PMID:
29697740
4.

Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue.

Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA.

Oncotarget. 2017 May 17;8(36):60036-60045. doi: 10.18632/oncotarget.17958. eCollection 2017 Sep 1.

5.

New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs).

Negri T, Brich S, Bozzi F, Volpi CV, Gualeni AV, Stacchiotti S, De Cecco L, Canevari S, Gloghini A, Pilotti S.

Oncotarget. 2017 May 16;8(20):32492-32504. doi: 10.18632/oncotarget.16477.

6.

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.

Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8.

PMID:
28284173
7.

Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.

Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C.

J Invest Dermatol. 2017 Feb;137(2):484-493. doi: 10.1016/j.jid.2016.06.634. Epub 2016 Sep 5.

8.

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.

Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, Belfiore A, Perrone F, Gualeni AV, Gloghini A, Cabras A, Brenca M, Maestro R, Zaffaroni N, Casali P, Bertulli R, Deraco M, Pilotti S.

Oncotarget. 2016 Nov 15;7(46):75503-75517. doi: 10.18632/oncotarget.12262.

9.

Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.

Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, Casali PG.

Ann Surg Oncol. 2016 Sep;23(9):2735-44. doi: 10.1245/s10434-016-5331-z. Epub 2016 Jun 22.

PMID:
27334221
10.

Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.

Spagnuolo RD, Brich S, Bozzi F, Conca E, Castelli C, Tazzari M, Maestro R, Brenca M, Gualeni AV, Gloghini A, Stacchiotti S, Pierotti MA, Pilotti S, Negri T.

Oncotarget. 2016 Jul 19;7(29):45015-45026. doi: 10.18632/oncotarget.7523.

11.

Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss.

Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R.

Mol Cancer Res. 2016 Sep;14(9):820-9. doi: 10.1158/1541-7786.MCR-16-0068. Epub 2016 Jun 2.

12.

Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).

Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG.

Clin Cancer Res. 2016 Feb 15;22(4):837-46. doi: 10.1158/1078-0432.CCR-15-1243. Epub 2015 Aug 10.

13.

Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.

Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, Stacchiotti S, Pierotti MA, Negri T, Pilotti S.

Mod Pathol. 2015 Aug;28(8):1074-83. doi: 10.1038/modpathol.2015.70. Epub 2015 May 29.

14.

Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.

Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, Colombo C, Crippa F, Morosi C, Casali PG, Pilotti S, Stacchiotti S, Rivoltini L, Castelli C.

BMC Cancer. 2015 Feb 14;15:58. doi: 10.1186/s12885-015-1044-0.

15.

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.

Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N.

Eur J Cancer. 2014 Nov;50(17):3021-8. doi: 10.1016/j.ejca.2014.09.004. Epub 2014 Sep 27.

PMID:
25269954
16.

Identification of a gene expression driven progression pathway in myxoid liposarcoma.

De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S.

Oncotarget. 2014 Aug 15;5(15):5965-77.

17.

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy.

Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, Gronchi A, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L, Castelli C.

Br J Cancer. 2014 Sep 23;111(7):1350-62. doi: 10.1038/bjc.2014.437. Epub 2014 Aug 7.

18.

Activity of sunitinib in extraskeletal myxoid chondrosarcoma.

Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali PG.

Eur J Cancer. 2014 Jun;50(9):1657-64. doi: 10.1016/j.ejca.2014.03.013. Epub 2014 Apr 2.

PMID:
24703573
19.

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.

Stacchiotti S, Dagrada GP, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S, Casali PG.

Clin Sarcoma Res. 2013 Dec 18;3(1):16. doi: 10.1186/2045-3329-3-16.

20.

Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma.

Castelli C, Tazzari M, Negri T, Vergani B, Rivoltini L, Stacchiotti S, Pilotti S.

J Transl Med. 2013 Sep 27;11:237. doi: 10.1186/1479-5876-11-237.

21.

Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.

Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, Casali PG.

Clin Cancer Res. 2013 Sep 15;19(18):5192-201. doi: 10.1158/1078-0432.CCR-13-0776. Epub 2013 Jul 25.

22.

Response to chemotherapy of solitary fibrous tumour: a retrospective study.

Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, Casali PG.

Eur J Cancer. 2013 Jul;49(10):2376-83. doi: 10.1016/j.ejca.2013.03.017. Epub 2013 Apr 6.

PMID:
23566418
23.

Phase II study on lapatinib in advanced EGFR-positive chordoma.

Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, Gronchi A, Pilotti S, Casali PG.

Ann Oncol. 2013 Jul;24(7):1931-6. doi: 10.1093/annonc/mdt117. Epub 2013 Apr 4.

24.

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib.

Stacchiotti S, Dagrada GP, Morosi C, Negri T, Romanini A, Pilotti S, Gronchi A, Casali PG.

Clin Sarcoma Res. 2012 Oct 11;2(1):22. doi: 10.1186/2045-3329-2-22.

25.

Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.

Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, Hohenberger P.

Ann Surg Oncol. 2013 Feb;20(2):586-92. doi: 10.1245/s10434-012-2647-1. Epub 2012 Sep 11.

PMID:
22965573
26.

Sunitinib malate in solitary fibrous tumor (SFT).

Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG.

Ann Oncol. 2012 Dec;23(12):3171-9. doi: 10.1093/annonc/mds143. Epub 2012 Jun 17.

27.

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.

Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S.

Oncogene. 2013 Mar 21;32(12):1475-87. doi: 10.1038/onc.2012.181. Epub 2012 Jun 4. Review.

PMID:
22665053
28.

High-grade sarcomatous overgrowth in solitary fibrous tumors: a clinicopathologic study of 10 cases.

Collini P, Negri T, Barisella M, Palassini E, Tarantino E, Pastorino U, Gronchi A, Stacchiotti S, Pilotti S.

Am J Surg Pathol. 2012 Aug;36(8):1202-15. doi: 10.1097/PAS.0b013e31825748f0.

PMID:
22613995
29.

DHM simulation in virtual environments: a case-study on control room design.

Zamberlan M, Santos V, Streit P, Oliveira J, Cury R, Negri T, Pastura F, Guimar√£es C, Cid G.

Work. 2012;41 Suppl 1:2243-7. doi: 10.3233/WOR-2012-0446-2243.

PMID:
22317048
30.

Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.

Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, Gronchi A, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S.

Genes Chromosomes Cancer. 2012 Feb;51(2):111-26. doi: 10.1002/gcc.20933. Epub 2011 Nov 1.

PMID:
22045652
31.

High CD133 expression levels in gastrointestinal stromal tumors.

Bozzi F, Conca E, Manenti G, Negri T, Brich S, Gronchi A, Pierotti MA, Tamborini E, Pilotti S.

Cytometry B Clin Cytom. 2011 Jul-Aug;80(4):238-47. doi: 10.1002/cyto.b.20589. Epub 2011 Apr 1.

32.

Targeted therapy in GIST: in silico modeling for prediction of resistance.

Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S.

Nat Rev Clin Oncol. 2011 Mar;8(3):161-70. doi: 10.1038/nrclinonc.2011.3. Review.

PMID:
21364689
33.

Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients.

Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, Orsenigo M, Filipazzi P, Pastore E, Pompilio M, Bossi P, Locati LD, Cantu' G, Scaramellini G, Pilotti S, Tagliabue E.

Ann Oncol. 2011 Aug;22(8):1886-93. doi: 10.1093/annonc/mdq756. Epub 2011 Feb 22.

34.

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.

Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG, Pilotti S.

Ann Oncol. 2011 Jul;22(7):1682-90. doi: 10.1093/annonc/mdq644. Epub 2011 Jan 17.

35.

Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.

Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S, Casali PG.

Int J Cancer. 2011 Oct 1;129(7):1761-72. doi: 10.1002/ijc.25826. Epub 2011 Mar 8. Erratum in: Int J Cancer. 2017 May 15;140(10 ):E13.

36.

Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification.

Negri T, Tarantino E, Orsenigo M, Reid JF, Gariboldi M, Zambetti M, Pierotti MA, Pilotti S.

Genes Chromosomes Cancer. 2010 Oct;49(10):901-9. doi: 10.1002/gcc.20798.

PMID:
20589936
37.

Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.

Negri T, Virdis E, Brich S, Bozzi F, Tamborini E, Tarantino E, Jocollè G, Cassinelli G, Grosso F, Sanfilippo R, Casalini P, Greco A, Pierotti MA, Pilotti S.

Clin Cancer Res. 2010 Jul 15;16(14):3581-93. doi: 10.1158/1078-0432.CCR-09-2912. Epub 2010 Jun 3.

38.

Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study.

Dileo P, Pricl S, Tamborini E, Negri T, Stacchiotti S, Gronchi A, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S.

Int J Cancer. 2011 Feb 15;128(4):983-90. doi: 10.1002/ijc.25418.

39.

Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.

Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S.

Mol Cancer Ther. 2010 May;9(5):1286-97. doi: 10.1158/1535-7163.MCT-09-1205.

40.

Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, Casali PG, Pierotti MA, Pilotti S.

Neuro Oncol. 2010 Aug;12(8):776-89. doi: 10.1093/neuonc/noq003. Epub 2010 Feb 17.

41.

Tumor response to sunitinib malate observed in clear-cell sarcoma.

Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, Casali PG.

Ann Oncol. 2010 May;21(5):1130-1. doi: 10.1093/annonc/mdp611. Epub 2010 Jan 21. No abstract available.

42.

Targeted therapies: the rare cancer paradigm.

Pierotti MA, Negri T, Tamborini E, Perrone F, Pricl S, Pilotti S.

Mol Oncol. 2010 Feb;4(1):19-37. doi: 10.1016/j.molonc.2009.10.003. Epub 2009 Oct 28. Review.

43.

Activate and resist: L576P-KIT in GIST.

Conca E, Negri T, Gronchi A, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Pricl S, Pilotti S.

Mol Cancer Ther. 2009 Sep;8(9):2491-5. doi: 10.1158/1535-7163.MCT-09-0662. Epub 2009 Sep 1.

44.

Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).

Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, Bossi P, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L.

Oral Oncol. 2009 Nov;45(11):986-90. doi: 10.1016/j.oraloncology.2009.05.635. Epub 2009 Jul 1.

PMID:
19574086
45.

T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.

Negri T, Pavan GM, Virdis E, Greco A, Fermeglia M, Sandri M, Pricl S, Pierotti MA, Pilotti S, Tamborini E.

J Natl Cancer Inst. 2009 Feb 4;101(3):194-204. doi: 10.1093/jnci/djn477. Epub 2009 Jan 27.

PMID:
19176456
46.

Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?

Miselli F, Negri T, Gronchi A, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, Tamborini E, Pilotti S.

Transl Oncol. 2008 Dec;1(4):177-86.

47.

Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).

Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S.

J Pathol. 2009 Jan;217(1):103-12. doi: 10.1002/path.2450.

PMID:
18973210
48.

TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.

Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, Licitra L, Pilotti S.

Transl Oncol. 2008 Sep;1(3):121-8.

49.

Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation.

Bozzi F, Ferrari A, Negri T, Conca E, Luca da R, Losa M, Casieri P, Orsenigo M, Lampis A, Meazza C, Casanova M, Pierotti MA, Tamborini E, Pilotti S.

Transl Oncol. 2008 Jul;1(2):95-101.

50.

PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors.

Miselli F, Millefanti C, Conca E, Negri T, Piacenza C, Pierotti MA, Tamborini E, Pilotti S.

Am J Surg Pathol. 2008 May;32(5):738-43. doi: 10.1097/PAS.0b013e31815c47e8.

PMID:
18360281

Supplemental Content

Support Center